Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHERRY-PICK: PHESGO in HER2+ Early Breast Cancer
NCT06068985Phase 2Active, not recruiting
- Sponsor
- Latin American Cooperative Oncology Group
- Start
- Sep 2024
- Primary completion
- Apr 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab in HER2-positive breast cancer, sponsored by Latin American Cooperative Oncology Group. Started Sep 2024; status: active, not recruiting.
02
Drugs
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT06068985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06068985.